In light of the Company’s simplified capital structure, solid balance sheet and profitable growth in the thyroid testing franchise, Interpace intends to seek an uplisting to the Nasdaq Stock Market in 2026 although no assurance can be given that the uplisting will be successfully achieved.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXG: